Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Natera, Inc. develops and commercializes cell-free DNA and genetic testing for oncology, women’s health and organ health. Company updates commonly cover financial results, revenue trends, laboratory operations and publications supporting tests such as Signatera, Prospera, Panorama and Horizon.
Recurring news also includes oncology molecular residual disease applications, clinical evidence presented at medical meetings, transplant rejection surveillance data, collaborations using Natera assays in drug trials, and patent or litigation developments tied to its MRD technology. The company reports through CLIA-certified and CAP-accredited laboratory operations and through Foresight Diagnostics, its subsidiary.
Natera, Inc. (NASDAQ: NTRA) has announced the initiation of patient enrollment in two clinical trials: CIRCULATE-Japan and BESPOKE CRC. The CIRCULATE-Japan trial is a multi-center study with 2,500 participants focused on ctDNA-guided treatment strategies for resectable colorectal cancer (CRC) in Japan. Similarly, BESPOKE CRC aims to enroll over 1,000 patients, assessing the impact of blood-based testing for early relapse detection. Both trials highlight the growing interest and potential of Signatera technology, which may improve treatment outcomes for CRC patients globally.
Natera, Inc. (NASDAQ: NTRA) has filed a patent infringement lawsuit against Progenity, Inc. in the U.S. District Court for the Western District of Texas. The suit claims that Progenity's non-invasive prenatal test infringes on six patents held by Natera. These include U.S. Patents 9,228,234; 9,424,392; 10,227,652; 10,240,202; 10,266,893; and 10,522,242. Natera is seeking both injunctive relief and monetary damages.